Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD, USA.
Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
J Natl Cancer Inst Monogr. 2024 Aug 1;2024(65):180-190. doi: 10.1093/jncimonographs/lgae034.
The Surveillance, Epidemiology, and End Results (SEER) Program with the National Cancer Institute tested whether population-based cancer registries can serve as honest brokers to acquire tissue and data in the SEER-Linked Virtual Tissue Repository (VTR) Pilot.
We collected formalin-fixed, paraffin-embedded tissue and clinical data from patients with pancreatic ductal adenocarcinoma (PDAC) and breast cancer (BC) for two studies comparing cancer cases with highly unusual survival (≥5 years for PDAC and ≤30 months for BC) to pair-matched controls with usual survival (≤2 years for PDAC and ≥5 years for BC). Success was defined as the ability for registries to acquire tissue and data on cancer cases with highly unusual outcomes.
Of 98 PDAC and 103 BC matched cases eligible for tissue collection, sources of attrition for tissue collection were tissue being unavailable, control paired with failed case, second control that was not requested, tumor necrosis ≥20%, and low tumor cellularity. In total, tissue meeting the study criteria was obtained for 70 (71%) PDAC and 74 (72%) BC matched cases. For patients with tissue received, clinical data completeness ranged from 59% for CA-19-9 after treatment to >95% for margin status, whether radiation therapy and chemotherapy were administered, and comorbidities.
The VTR Pilot demonstrated the feasibility of using SEER cancer registries as honest brokers to provide tissue and clinical data for secondary use in research. Studies using this program should oversample by 45% to 50% to obtain sufficient sample size and targeted population representation and involve subspecialty matter expert pathologists for tissue selection.
美国国家癌症研究所的监测、流行病学和最终结果（SEER）计划测试了基于人群的癌症登记处是否可以作为诚实的中间人，在 SEER 关联虚拟组织库（VTR）试点中获取组织和数据。
我们为两项研究收集了胰腺导管腺癌（PDAC）和乳腺癌（BC）患者的福尔马林固定、石蜡包埋组织和临床数据，这些研究比较了生存时间异常（PDAC 为≥5 年，BC 为≤30 个月）的癌症病例与生存时间通常（PDAC 为≤2 年，BC 为≥5 年）的配对对照。成功的定义是登记处获取具有异常高结局的癌症病例的组织和数据的能力。
在 98 例 PDAC 和 103 例 BC 匹配病例中，组织收集的流失源是组织不可用、与失败病例配对的对照、未请求的第二个对照、肿瘤坏死率≥20%和低肿瘤细胞性。总共，符合研究标准的组织获得了 70 例（71%）PDAC 和 74 例（72%）BC 匹配病例。对于接受组织的患者，临床数据的完整性范围从治疗后 CA-19-9 的 59%到边缘状态、是否进行放射治疗和化学治疗以及合并症的>95%。
VTR 试点证明了使用 SEER 癌症登记处作为诚实的中间人提供组织和临床数据用于研究的二次使用的可行性。使用该计划的研究应额外抽取 45%至 50%的样本量，以获得足够的样本量和目标人群代表性，并涉及组织选择的专业病理学家。
